Galderma Bolsters Its Skincare-To-Syringes Portfolio With $1.5B Deal For ZO Skin Health

Galderma has agreed to acquire ZO Skin Health in a $1.5 billion deal that brings together two of the five leading professional skincare brands in the United States, diversifies the dermatology giant’s business amid softness in the facial fillers market and strengthens its position at the intersection of skincare and medical aesthetics. The purchase price falls below the roughly $2 billion valuation Reuters reported in September that a sale of ZO could fetch. Still, the deal values the brand at approximately 4.5 times its net sales of $330 million for the 12 months ended June 2026. Blackstone, which acquired a majority stake in ZO in 2020 for an undisclosed sum when the brand was projected to register approximately $140 million in annual sales, is selling the business alongside the Obagi family. The all-cash transaction is expected to close in the fourth quarter of 2026 or early 2027. Industry sources estimate ZO’s earnings before interest, taxes, depreciation and amortization (EBITDA) margin at roughly 20%, implying annual EBITDA of approximately $66 million and, using that estimate, an acquisition multiple of nearly 23 times EBITDA. By comparison, DC Advisory calculates beauty transactions this year have commanded median valuations of approximately 3 to 4 times revenue and 12.5 to 14.5 times EBITDA. “Galderma isn’t simply acquiring another skincare brand,” says David Valenzuela, founder and CEO of professional skincare brand WISH Skin Health . “It’s acquiring an established professional distribution network, a strong education platform and the trust ZO has built with physicians and skincare professionals. Relationships are incredibly difficult to replicate, and they represent significant long-term value.” ZO Skin Health, which Galderma has agreed to acquire for $1.5 billion, offers more than 40 skincare products distributed through physicians, med-spas and online accounts. Together with Alastin, it will give Galderma a 19% share of the U.S. medical care provider skincare channel, according to Kline + Co. Hayden Williams, partner at BrandProject , a venture capital firm with Thea, Peachy, Iris&Romeo and Great Many in its portfolio, points to ZO’s staying power as a critical factor in its appeal to Galderma. Founded by dermatologist Zein Obagi in 2007, ZO’s assortment of more than 40 products spans cleansers, exfoliators, retinol treatments and corrective serums, with individual products ranging from about $50 to $265. Its distribution network spans more than 16,500 physician, medical spa and online accounts in over 40 countries. “Skincare shoppers are not known for their loyalty. Every week brings a new TikTok trend, a new hero ingredient, a new brand promising glass skin by Friday. Most brands end up paying to win the same customer over and over again,” says Williams. “A brand whose customers actually stick around is rare, and rare is expensive, which is where physician-dispensed skincare has an edge.” Keith O’Briant, founder and CEO of professional skincare brand Hydrinity , considers the 4.5 times sales multiple strong in a market focused on financial discipline. He also sees the deal as indicative of the direction skincare and aesthetics companies are going, bridging aspects of the business that were previously separate. “[At aesthetic practices], you can’t just have a skincare, a device or a needle...All of our partners are multimodality. Why not organizations?” he says, adding that integrating offerings “allows you to have bundles. It just gives you more market share, and you can command more of a presence. And when you have more offerings, then you have a way to protect your top-line business.” “A brand whose customers actually stick around is rare, and rare is expensive, which is where physician-dispensed skincare has an edge.” Galderma shares rose 2.7% Wednesday following the acquisition announcement, closing at 171.85 Swiss francs on the SIX Swiss Exchange. The company expects the ZO acquisition to slightly dilute its core EBITDA margin in 2027. The margin stood at 25.6% in the first half of 2026. Galderma plans to increase commercial investment in ZO during its first year of ownership, with renewed growth anticipated in its second year and the brand’s core EBITDA margin expected to become broadly comparable to Galderma’s beginning in 2028. Galderma generated $3.13 billion in net sales in the first half of 2026, with injectable aesthetics, including neuromodulators Dysport and Relfydess, hyaluronic acid filler Restylane and collagen stimulator Sculptra, accounting for $1.44 billion, or 46% of the total. Dermatological skincare, which includes drugstore staple Cetaphil and major professional skincare brand Alastin, generated $848 million, or 27%, and therapeutic dermatology contributed another $848 million. At constant currency, sales grew 12.1% in injectable aesthetics, 16.4% in dermatological skincare and 67.9% in therapeutic dermatology. The United States accounted for $1.37 billion, or nearly 44%, of Galderma’s first-half sales, up 32.3% from a year earlier. Growth in its fillers and biostimulators business slowed to 7.6% in the second quarter from 14% in the first quarter, reflecting continued softness in the fillers market. French beauty giant L’Oréal holds a 20% stake in Galderma after doubling its investment earlier this year. ZO is among a limited group of professional skincare brands with the scale, reputation and market standing to attract a buyer like Galderma. Industry sources say aesthetics company Revance bid on the brand, too. Galderma acquired Alastin for approximately $470.5 million in a deal completed in 2021, or roughly 9.4 times its projected annual sales at the time. Dealmaking in professional skincare is expected to continue, with Hydrinity among the brands identified as potential acquisition targets. The company expects sales to grow more than 40% this year and has been profitable since its second year, according to founder and CEO Keith O’Briant. ZO’s combination with Alastin will give Galderma a 19% share of the medical care provider skincare channel in the U.S., up 12.7 percentage points, according to Kline + Co. The U.S. professional skincare market as a whole generated $2.6 billion in manufacturers’ sales in 2025 and is projected to grow at a compound annual rate of 6% through 2030, the firm forecasts. Medical care providers represent the largest distribution channel in the market, ahead of retail and spas and salons. Professional skincare generated nearly $2.5 billion in in-store sales at U.S. medical aesthetics practices and accounted for 12% of total nonsurgical patient spending at those locations, according to Guidepoint Qsight . Although substantially smaller than the estimated $38 billion U.S. skincare market, professional skincare has higher barriers to entry, typically requiring dedicated salesforces, clinical backing and extensive practitioner education. “Skincare has moved from an add-on to a core part of how practices build treatment programs and keep patients engaged between visits,” says Erika Sheyn, SVP of aesthetics at Guidepoint Qsight. “With a popular injectables portfolio and its own professional skincare brand, Galderma’s addition of ZO Skin Health to its group enables it to reach even further across the patient journey beyond focusing on treatment support and into patients’ daily regimens.” Industry insiders predict greater consolidation in professional skincare and aesthetics, categories considered relatively resilient in periods of economic uncertainty. In a survey conducted in the second quarter of 2026 among subscribers to its BeautyEngine platform, NewBeauty found that 51.5% of aesthetic patients had become more careful with spending over the preceding six months, but only 11% ranked aesthetic treatments among their first spending cuts. “Brands that can demonstrate meaningful scientific differentiation and proven clinical outcomes continue to command a premium.” Waldencast sold Obagi Medical to private equity firm Bridgepoint in July for up to $460 million or about 2.8 times its 2025 sales. Zein Obagi founded Obagi Medical prior to ZO in 1988. The same month, Epicutis closed a $25 million series C round with GroundForce Capital. Revision Skincare, Hydrinity and Plated Skin Science have been mentioned as potential deal targets. Yann Pencolé, VP of beauty and wellbeing advisory at Kline, writes in an online post on the ZO transaction that “the deal is expected to accelerate consolidation across the market, making scale, clinical evidence and professional partnerships critical differentiators as integrated care models shape the future of the industry.” Luc-Henry Rousselle, managing director on the consumer, leisure and retail team at DC Advisory, an investment bank that advised Epicutis on its series C, says, “The buyer universe has expanded beyond traditional beauty companies to include participants across aesthetics, dermatology and healthcare, creating a highly attractive strategic landscape. As a result, brands that can demonstrate meaningful scientific differentiation and proven clinical outcomes continue to command a premium, and we believe that dynamic will persist as the lines between beauty, wellness and medical aesthetics become increasingly blurred.” One of Galderma’s challenges following the ZO acquisition will be maintaining differentiation between ZO and Alastin to drive growth at both brands. A Galderma spokesperson suggests the brands’ distinct products and distribution networks should help minimize cannibalization. Acquisitions of professional skincare brands can raise concerns among physicians and med-spas about changes to products, pricing and business relationships. Ozan Sozer, founder of El Paso Cosmetic Surgery, doesn’t anticipate significant drawbacks for practices following Galderma’s acquisition of ZO Skin Health and believes established Galderma accounts could benefit from purchasing advantages. © Christ Chavez “We see the brands as highly complementary,” says the spokesperson. “ZO Skin Health’s daily, regimen-based portfolio is centered on retinol- and acid-based protocols while Alastin’s peptide-based offering is focused on regenerative pre- and post-procedure use. They also have complementary commercial strengths, with ZO strong in med spas and Alastin more established among dermatologists and plastic surgeons. Together, they would enable Galderma to better serve healthcare professionals and their patients.” Another challenge will be reassuring healthcare providers and medical spas that sell ZO’s products about what the change in ownership could mean for their businesses. However, Ozan Sozer, a plastic surgeon, president-elect of the International Society of Aesthetic Plastic Surgery and founder of El Paso Cosmetic Surgery , isn’t particularly concerned about the acquisition’s impact on practices. Sozer notes that acquisitions are common in medical aesthetics and thinks Galderma can leverage its existing relationships with physicians to market ZO’s products. “Galderma will most likely be able to market them very efficiently considering their strong presence in the market,” he says. “I do not see any benefit or drawback for practices, maybe some purchasing advantages for established Galderma accounts.”